Company intelligence / Profile preview

CanThera Cancer Therapy Center

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

CanThera is a biotechnology company focused on developing next-generation cancer therapies by targeting critical regulators of the cell cycle. The company's lead program involves the development of highly selective inhibitors of Polo-like kinase 1 (PLK1), a protein often overexpressed in various aggressive cancers. By utilizing a unique binding mechanism, CanThera aims to overcome the toxicity and efficacy limitations associated with earlier generations of PLK inhibitors. Their research primarily targets difficult-to-treat indications such as triple-negative breast cancer and non-small cell lung cancer.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on CanThera Cancer Therapy Center.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CanThera Cancer Therapy Center.

Explore the full profile